Scandion Oncology Feed

Land	Danmark
Lista	First North Stockholm
Sektor	Hälsovård
Industri	Bioteknik

2024-07-11 08:00:00 SCANDION ONCOLOGY'S RIGHTS ISSUE REGISTERED WITH THE DANISH BUSINESS AUTHORITY +0,96% | 0,05 MSEK

2024-07-01 17:30:00 Scandion Oncology board member Michel Ducreux steps down, joins advisory board -10,34% | 0,07 MSEK

2024-06-25 17:30:00 SCANDION ONCOLOGY ANNOUNCES OUTCOME OF THE RIGHTS ISSUE -24,08% | 0,27 MSEK

2024-06-03 17:00:00 Scandion announces change of Certified Adviser to Vator Securities +8,33% | 0,13 MSEK

2024-05-31 12:00:00 SCANDION ONCOLOGY PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE +182,67% | 0,19 MSEK

2024-05-23 22:30:00 SCANDION ONCOLOGY ANNOUNCES THE FINAL TERMS OF THE RIGHTS ISSUE -25,21% | 0,93 MSEK

2024-05-22 07:00:00 Scandion Oncology – Interim Report Q1 2024 +4,64% | 0,27 MSEK

2024-05-16 17:00:00 Invitation to Scandion Oncology webcast and conference call May 22, 2024 +0,37% | 0,02 MSEK

2024-05-13 07:00:00 Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101 +2,58% | 0,19 MSEK

2024-05-06 16:30:00 Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors +0,76% | 0,08 MSEK

2024-05-03 08:00:00 Scandion Oncology to Host R&D Update May 15 +1,16% | 0,05 MSEK

2024-04-19 08:30:00 Scandion Oncology – Notice convening the Annual General Meeting -35,48% | 1,98 MSEK

2024-04-19 08:00:00 SCANDION ONCOLOGY CARRIES OUT A RIGHTS ISSUE OF APPROXIMATELY SEK 60 MILLION SECURED UP TO APPROXIMATELY SEK 30.6 MILLION -35,48% | 1,98 MSEK

2024-03-21 07:00:00 Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival +5,44% | 0,23 MSEK

2024-03-15 07:00:00 Scandion Oncology - Annual Report 2023 +1,90% | 0,06 MSEK

2024-03-07 07:00:00 Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial +2,81% | 0,41 MSEK

2024-02-28 07:00:00 Scandion Oncology – Q4 & yearend report 2023 -8,65% | 0,16 MSEK

2024-02-22 16:00:00 Invitation to Scandion Oncology webcast and conference call February 28, 2024 +13,85% | 0,37 MSEK

2024-01-31 07:00:00 Scandion Oncology reports positive topline Phase IIa data from the CORIST Part 3 trial +3,97% | 9,51 MSEK

2024-01-05 08:30:00 Scandion Oncology receives Notice of Allowance for patent to enhance US patent exclusivity on SCO-101 +12,25% | 0,89 MSEK

2023-12-21 17:30:00 CORIST part 3 topline data are expected in the second half of January 2024 +14,25% | 6,65 MSEK

2023-12-15 08:30:00 Scandion Oncology identifies potentially effective treatment of gastric cancer +22,28% | 1,91 MSEK

2023-11-29 08:30:00 Scandion Oncology is granted new Composition of Matter-patent on lead compound SCO-101 extending its exclusivity until at least 2042 +7,96% | 0,28 MSEK

2023-11-22 08:30:00 Scandion Oncology – Interim Report Q3 2023 -2,30% | 0,90 MSEK

2023-11-21 08:30:00 Final data from the Phase IIa open-label CORIST part 2 trial shows impressive median Overall Survival of 10.4 months +45,73% | 1,99 MSEK

2023-11-15 16:00:00 Invitation to Scandion Oncology webcast and conference call November 22, 2023 -3,89% | 0,06 MSEK

2023-10-16 00:05:00 Phase Ib PANTAX trial is successfully completed and establishes the maximal tolerated dose with positive safety profile and pharmacokinetic data. -1,53% | 0,13 MSEK

2023-09-12 07:00:00 Scandion Oncology appoints Lars Damstrup, MD, PhD, as new Chief Medical Officer +1,66% | 0,05 MSEK

2023-08-23 08:30:00 Scandion Oncology – Interim Report Q2 2023 +2,11% | 0,10 MSEK

2023-08-17 08:30:00 Data from PANTAX trial to be presented at ESMO Congress 2023 -1,13% | 0,08 MSEK

2023-08-16 08:30:00 Invitation to Scandion Oncology webcast and conference call August 23, 2023 +3,23% | 0,07 MSEK

2023-07-18 07:00:00 The European Patent Office announces intention to grant of Composition-of-Matter patent for Scandion Oncology’s lead compound SCO-101 +8,90% | 0,07 MSEK

2023-05-26 08:30:00 Scandion Oncology – Interim Report Q1 2023 -1,66% | 0,14 MSEK

2023-05-19 08:30:00 Invitation to Scandion Oncology webcast and conference call May 26, 2023 -3,09% | 0,06 MSEK

2023-04-26 17:30:00 Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors -2,54% | 0,06 MSEK

2023-04-11 08:30:00 Scandion Oncology – Notice convening the Annual General Meeting -6,91% | 0,33 MSEK

2023-03-31 10:00:00 Scandion Oncology successfully completes the dose finding with lead compound SCO-101 in advanced pancreatic cancer patients (PANTAX phase Ib trial) -1,39% | 0,71 MSEK

2023-03-28 08:30:00 Scandion Oncology - Annual Report 2022 -11,89% | 0,19 MSEK

2023-03-21 08:30:00 Invitation to Scandion Oncology webcast and conference call March 28, 2023 -2,00% | 0,19 MSEK

2023-02-22 08:30:00 Scandion Oncology – Q4 & year-end report 2022 +7,08% | 0,18 MSEK

2023-02-15 14:30:00 Invitation to Scandion Oncology webcast and conference call February 22, 2023 -3,64% | 0,30 MSEK

2023-01-19 13:00:00 Scandion Oncology A/S: Scandion Oncology receives favorable opinion from the European Patent Office on Composition of Matter Patent-application for lead compound SCO-101 +3,63% | 1,05 MSEK

2023-01-18 14:00:00 Scandion Oncology A/S: Scandion Oncology appoints Jan Stenvang, Ph.D., Chief Scientific Officer and member of Executive Management -1,19% | 0,14 MSEK

2022-12-05 08:30:00 Scandion Oncology announces share purchase by incoming President & CEO +0,32% | 0,31 MSEK

2022-12-01 08:30:00 Scandion Oncology appoints Francois Martelet, M.D., as new Chief Executive Officer +7,43% | 3,47 MSEK

2022-11-23 08:30:00 Scandion Oncology announces share purchase by member of the Board of Directors +7,47% | 0,77 MSEK

2022-11-16 08:30:00 Scandion Oncology – Interim Report Q3 2022 -3,88% | 0,30 MSEK

2022-11-10 08:30:00 Invitation to Scandion Oncology webcast and conference call November 16, 2022 +0,43% | 0,18 MSEK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

2025-02-28	Bokslutskommuniké 2024
2024-11-27	Kvartalsrapport 2024-Q3
2024-08-29	Kvartalsrapport 2024-Q2
2024-05-22	Kvartalsrapport 2024-Q1
2024-04-25	X-dag ordinarie utdelning SCOL 0.00 SEK
2024-04-24	Årsstämma 2024
2024-02-28	Bokslutskommuniké 2023
2023-11-22	Kvartalsrapport 2023-Q3
2023-08-23	Kvartalsrapport 2023-Q2
2023-05-26	Kvartalsrapport 2023-Q1
2023-04-27	X-dag ordinarie utdelning SCOL 0.00 SEK
2023-04-26	Årsstämma 2023
2023-02-22	Bokslutskommuniké 2022
2022-11-16	Kvartalsrapport 2022-Q3
2022-08-25	Kvartalsrapport 2022-Q2
2022-05-19	Kvartalsrapport 2022-Q1
2022-04-28	X-dag ordinarie utdelning SCOL 0.00 SEK
2022-04-27	Årsstämma 2022
2022-02-17	Bokslutskommuniké 2021
2021-11-18	Kvartalsrapport 2021-Q3
2021-11-17	Extra Bolagsstämma 2021
2021-08-19	Kvartalsrapport 2021-Q2
2021-05-27	X-dag ordinarie utdelning SCOL 0.00 SEK
2021-05-26	Årsstämma 2021
2021-05-20	Kvartalsrapport 2021-Q1
2021-02-18	Bokslutskommuniké 2020
2020-11-19	Kvartalsrapport 2020-Q3
2020-08-20	Kvartalsrapport 2020-Q2
2020-05-28	X-dag ordinarie utdelning SCOL 0.00 SEK
2020-05-27	Årsstämma 2020
2020-05-21	Kvartalsrapport 2020-Q1
2020-02-20	Bokslutskommuniké 2019
2019-11-21	Kvartalsrapport 2019-Q3
2019-08-22	Kvartalsrapport 2019-Q2
2019-06-11	Extra Bolagsstämma 2019
2019-05-31	X-dag ordinarie utdelning SCOL 0.00 SEK
2019-05-29	Årsstämma 2019
2019-05-27	Kvartalsrapport 2019-Q1
2019-02-21	Bokslutskommuniké 2018
2018-11-18	Kvartalsrapport 2018-Q3

Scandion Oncology

Prenumeration

Kalender

Beskrivning

Scandion Oncology

Prenumeration

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden